Table 3.

Univariate and multivariate prognostic factor analysis results

Factor	Univariate analysis			Multivariate analysis
	HR	95% CI	Pa	HR	95% CI	Pa
Age ≥ 65 years	1.138	0.922–1.403	0.229
Female sex	0.090	0.661–1.031	0.098
ECOG 0	0.638	0.486–0.839	0.001*	0.737	0.582–0.935	0.012*
Cancer type
Melanoma	0.646	0.517–0.807	< 0.001*	0.887	0.671–1.201	0.421
NSCLC	1.076	0.850–1.363	0.543
RCC	1.568	1.220–2.014	< 0.001*	1.230	0.930–1.627	0.146
Other	1.152	0.869–1.527	0.325
Stage IV	2.029	0.960–4.289	0.064
ICI
Nivolumab	1.055	0.853–1.306	0.620
Pembrolizumab	0.981	0.787–1.222	0.861
Other	0.875	0.573–1.336	0.537
First-line treatment	0.640	0.508–0.806	< 0.001*	0.788	0.591–1.051	0.106
Pre-ICI RT	1.066	0.864–1.315	0.550	1.021	0.283–1.265	0.851
Occurrence of irAE	0.594	0.480–0.735	< 0.001*	0.620	0.499–0.769	< 0.001*
≥ 1 grade III-V irAE	0.866	0.658–1.140	0.304

The statistically significant p values are marked with an asterisk

HR Hazard ratio, CI Confidence interval, ECOG EASTERN Cooperative Oncology Group, pre-ICI Preceding immune checkpoint inhibitor treatment, irAE Immune-related adverse event

^ap values from univariate and multivariate Cox regression analyses